Thursday, Pfizer and French vaccine manufacturer Valneva reported the
results of a phase 2 safety trial showing that their vaccine candidate for
Lyme disease had successfully induced long-lasting immunity.
Companies evaluated the antibody levels of children and adults who received
two or three vaccine doses six months after the phase 2 trial ended in
April.
results of a phase 2 safety trial showing that their vaccine candidate for
Lyme disease had successfully induced long-lasting immunity.
Companies evaluated the antibody levels of children and adults who received
two or three vaccine doses six months after the phase 2 trial ended in
April.
